

Substitute for form 1449/PTO

### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	1	of	1
-------	---	----	---

**Complete if Known**

Application Number	10/529,221
Filing Date	June 30, 2006
First Named Inventor	ROBERT, Bruno
Art Unit	1644
Examiner Name	DIBRINO, Marianne N.
Attorney Docket Number	1843.0200001/EKS/EJH

## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

742438 1

Examiner Signature	/Marianne DiBrino/	Date Considered	08/17/2009
-----------------------	--------------------	--------------------	------------

[illegible]

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



Equivalent of Form PTO/SB/088 (10-07)

Approved for use through 10/31/2007. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

### THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

#### Complete if Known

Application Number	10/529,221
Filing Date	June 30, 2006
First Named Inventor	ROBERT, Bruno
Art Unit	1644
Examiner Name	DIBRINO, Marianne N.
Attorney Docket Number	1843.0200001/EKS/EJH

#### NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
/M.D./	NPL93	HOFFMAN, P., <i>et al.</i> , "Large-scale in vitro expansion of polyclonal human CD4 <sup>+</sup> CD25 <sup>high</sup> regulatory T cells," <i>Blood</i> 104:895-903, The American Society of Hematology (August 2004)	
/M.D./	NPL94	OGG, G.S., <i>et al.</i> , "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes," <i>Br. J. Cancer</i> 82:1058-1062, Cancer Research Campaign (2000)	
/M.D./	NPL95	TIMMERMAN, J.M., and LEVY, R., "Dendritic Cell Vaccines for Cancer Immunotherapy," <i>Annu. Rev. Med.</i> 50:507-529, Annual Reviews (1999)	
/M.D./	NPL96	ZEMON, H., "An artificial solution for adoptive immunotherapy," <i>Trends Biotechnol.</i> 21:418-420, Elsevier Science Publishers (October 2003)	

742459\_1

Examiner Signature	/Marianne DiBrino/	Date Considered	08/17/2009
--------------------	--------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.96. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.